Replies to post #224112 on Biotech Values

[blueyedcatch]

You have any proof that the warrants were swapped for free shares? If so,I say it`s time to get out the pitch forks and axes,and head to NJ. Ken needs to swing from a tree branch. This boils my blood. This SOB is the devil,and the worst wanna be CEO in the universe.

[ignatiusrielly35]

Dew, your scenario doesn’t address what ADXS is getting in return for swapping the warrants out. The selling restriction would be unnecessary without the swap because those new shares wouldn’t exist. It seems to me that the warrant holders that were not offered the 1:1 swap simply were not part of whatever the other warrant holders might have agreed to provide in return, pursuant to your scenario. But they had to lower the exercise price for them anyway due to the MFN clause. Thoughts?

[HereToFightScams]

I think the reason they chose to keep the warrants rather than free shares is that these warrants have the anti-dilution provision, the shares do not. These warrant holders figure their percentage of ownership won't change after the massive reverse split, but the new shareholders will lose out. It basically doesn't matter really since the company will go bk soon anyway.

[James salmon]

Dew,

I think timing will be everything, if RS comes with positive data and then maybe FDA approval for changes to trial and lifting of partial hold, then I think we could see a significant move north before a financing is done.

[swampboots]

Re: What is the ultimate prospects for ADXS-NEO and ADXS-PSA, in the stark terms of them delivering a personal profit to a common stock investor. In my opinion that stock investor is always the "door mat" for
the larger Big Pharma who has already made the ultimate superior deal, in an iron clad contract betting that the fruits of all of their royalty agreements, will be financed by newly minted common stock shareholders, betting on short term drug data results, as well as that royalty partner's ability to mastermind dribbling new strategies to survive further evolving configurated drug trials, which will cost the larger Pharma entity nothing more.

In sum, if ASXS stuff is ready to go now stockholders have excellent outcomes as well as the royalty partner. If ASDX stuff is still possibly great but must await one or a dozen future drug trial configurations, the common stock shareholders are the philanthropic donors in this glorious investment platform. And I use the word glorious admirably, as those armies of common shareholders masquerade as a pure pipeline, financing billions to enhance drug discovery and physical life improvements for billions of people.

[DewDiligence]

ADXS-NEO preliminary results (from poster presentation at AACR):

https://www.businesswire.com/news/home/20190329005416/en

Preliminary findings from the ADXS-NEO Phase 1 study include the following:

• Substantial anti-tumor immunity, including T cell responses to neoantigens and antigen spreading, was observed within one week of first dose at both dose levels.

• Dosing of ADXS-NEO at 1x10^8 colony forming units (CFU) has been well-tolerated in two patients.

• ADXS-NEO dosed at 1x10^9 CFU was beyond the maximum tolerated dose (MTD) (Reversible Grade 3 hypoxia (n=2) and Grade 3 hypotension (n=1) were dose-limiting toxicities.)

• Manufacturing of ADXS-NEO, comprised of 40 personal neoantigens, was successfully completed within seven to eight weeks for each subject.

“The patients being evaluated for safety and tolerability in Part A all have late-stage disease and have been treated with numerous prior therapies. As a result, we did not expect to observe significant clinical activity in this cohort,” said Andres Gutierrez, M.D. Ph.D., Chief Medical Officer of Advaxis. “Nevertheless, we have seen some encouraging clinical signals to date, including one patient at dose level 1 with non-small cell lung cancer who achieved stable disease after only two doses of ADXS-NEO, which is consistent with rapid immune activation.” He concluded, “This is the first presentation of clinical data from our ADXS-NEO program at a major medical conference. We are continuing to enroll subjects and gather additional clinical and immune correlative data, and plan to share updated data from this study throughout this year.”

The ADXS-NEO poster-presentation file will be available on Sunday (the date of the AACR presentation).

I expect ADXS to issue a PR on ADXS-PSA on Monday, when the ADXS-PSA data will be presented in a separate poster session.